Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Identification of Specific Biomarkers for Selective Clinical Interventions in Post- COVID-19 Patients
54 Pages Posted: 5 Oct 2022
More...Abstract
Background: In COVID-19 clinical symptoms can persist even after negativization. Currently, there are no specific diagnostic tests that characterize the complexity of post COVID-19 and address specific, interventions. We here investigated the biomarkers that define the post-COVID-19 clinical state.
Methods: We investigated the exhaled breath condensate (EBC) of 38 post COVID-19 patients and 38 sex and age-matched healthy controls via nuclear magnetic resonance (NMR)-based metabolomics. Predicted gene-modulated microRNAs (miRNAs) related to COVID-19 were quantified from EBC of 6 patients and 6 controls. Finally, clinical parameters from all post-COVID19 patients were correlated with metabolomic data.
Findings: Post-COVID-19 patients and controls showed different metabolic phenotype ('metabotype'), due to persistent inflammation. From them, by using enrichment analysis, we identified miR146a, miR-126 and miR-223, which resulted up-regulated (miR146a) and downregulated (miR-126 and miR-223) in post-COVID-19. Correlation of metabolites with clinical data confirmed that patients and controls presented different metabotypes, and that post-COVID-19 before rehabilitation is still characterized by persistent inflammation, dysregulation of liver, endovascular thrombotic and pulmonary processes, and physical impairment.
Interpretation: Joining EBC metabolomics, miRNAs and clinical data, we described the altered condition of post-COVID-19 patients. They are characterized by several pathophysiological processes, which should be primarily targeted to contrast the post-acute sequelae of COVID-19.
Funding Information: This work was partially supported by the “Ricerca corrente” funding scheme of the Ministry of Health, Italy.
Declaration of Interests: All the authors wish to declare no conflict of interest.
Ethics Approval Statement: We followed the STROBE reporting guidelines, 7 in line with the 1975 Declaration of Helsinki. The Ethic Committee of Istituto Nazionale Tumori, Fondazione Pascale, Naples, Italy approved the study (n. ICS 3/20). All study participants provided written informed consent.
Keywords: SARS-CoV-2, COVID-19, metabolomics, biomarkers, microRNAs, disability, rehabilitation, outcomes
Suggested Citation: Suggested Citation